Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer.

Tiffany M JuarezDavid PiccioniLara RoseAngel NguyenBradley BrownSantosh Kesari

Published in: Neuro-oncology advances (2021)

Dexanabinol administered weekly by intravenous infusion was safe and well-tolerated up to 28 mg/kg in brain cancer patients, but has limited antitumor activity in patients with brain cancer.

Keyphrases

papillary thyroid
resting state
white matter
functional connectivity
squamous cell
high dose
multiple sclerosis
lymph node metastasis
squamous cell carcinoma
young adults
childhood cancer